This statistic shows the probability of success for new drugs with and without biomarkers in the U.S. through the various stages of development, in the period from January 1, 2011, to November 30, 2020. It was found that while the probability that a new drug without biomarkers makes it from phase I to approval was only 7.6 percent, those with selection biomarkers had a probability of success of 15.9 percent.
Probability of success for new drugs in the U.S. with and without selection biomarkers by development phase between 2011 and 2020
Characteristic
With biomarkers
Without biomarkers
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Exclusive Premium Statistic
To access all Premium Statistics, you need a paid Statista Account
Only company-sponsored, FDA registration-enabling development
programs were included in this analysis. Investigator-sponsored studies and combinations with other
investigational drugs were excluded.
* NDA - New Drug Application / BLA - Biologic License Application.
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.
Learn more about how Statista can support your business.
Biotechnology Innovation Organization, & Pharma Intelligence, & QLS Advisors. (February 26, 2021). Probability of success for new drugs in the U.S. with and without selection biomarkers by development phase between 2011 and 2020 [Graph]. In Statista. Retrieved July 17, 2024, from https://www.statista.com/statistics/597826/drug-development-phases-probability-of-success-with-without-biomarkers/
Biotechnology Innovation Organization, und Pharma Intelligence, und QLS Advisors. "Probability of success for new drugs in the U.S. with and without selection biomarkers by development phase between 2011 and 2020." Chart. February 26, 2021. Statista. Accessed July 17, 2024. https://www.statista.com/statistics/597826/drug-development-phases-probability-of-success-with-without-biomarkers/
Biotechnology Innovation Organization, Pharma Intelligence, QLS Advisors. (2021). Probability of success for new drugs in the U.S. with and without selection biomarkers by development phase between 2011 and 2020. Statista. Statista Inc.. Accessed: July 17, 2024. https://www.statista.com/statistics/597826/drug-development-phases-probability-of-success-with-without-biomarkers/
Biotechnology Innovation Organization, and Pharma Intelligence, and QLS Advisors. "Probability of Success for New Drugs in The U.S. with and without Selection Biomarkers by Development Phase between 2011 and 2020." Statista, Statista Inc., 26 Feb 2021, https://www.statista.com/statistics/597826/drug-development-phases-probability-of-success-with-without-biomarkers/
Biotechnology Innovation Organization & Pharma Intelligence & QLS Advisors, Probability of success for new drugs in the U.S. with and without selection biomarkers by development phase between 2011 and 2020 Statista, https://www.statista.com/statistics/597826/drug-development-phases-probability-of-success-with-without-biomarkers/ (last visited July 17, 2024)
Probability of success for new drugs in the U.S. with and without selection biomarkers by development phase between 2011 and 2020 [Graph], Biotechnology Innovation Organization, & Pharma Intelligence, & QLS Advisors, February 26, 2021. [Online]. Available: https://www.statista.com/statistics/597826/drug-development-phases-probability-of-success-with-without-biomarkers/
